NASDAQ · LENZ
Healthcare · Biotechnology
$3.05
Up+$0.00 (+0.00%)
Updated Nov 3, 2026, 7:36 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LENZ
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
LENZ closed at $3.05 after 21 trading sessions, down 15.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $3.07 | $3.19 | $2.80 | $3.05 | 2.26M |
| Oct 30, 2026 | $3.38 | $3.425 | $3.04 | $3.05 | 2.26M |
| Oct 29, 2026 | $3.00 | $3.58 | $2.995 | $3.49 | 5.99M |
| Oct 28, 2026 | $3.10 | $3.2191 | $3.07 | $3.21 | 573.9K |
| Oct 27, 2026 | $3.13 | $3.19 | $3.075 | $3.15 | 377.75K |
| Oct 26, 2026 | $3.16 | $3.195 | $3.095 | $3.145 | 389.15K |
| Oct 23, 2026 | $3.23 | $3.23 | $3.06 | $3.16 | 696.46K |
| Oct 22, 2026 | $3.25 | $3.285 | $3.18 | $3.25 | 435.47K |
| Oct 21, 2026 | $3.20 | $3.37 | $3.145 | $3.22 | 943.35K |
| Oct 20, 2026 | $3.27 | $3.33 | $3.12 | $3.19 | 819.37K |
| Oct 19, 2026 | $3.27 | $3.40 | $3.209 | $3.30 | 648.75K |
| Oct 16, 2026 | $3.56 | $3.56 | $3.21 | $3.27 | 939.08K |
| Oct 15, 2026 | $3.43 | $3.64 | $3.43 | $3.57 | 793.85K |
| Oct 14, 2026 | $3.39 | $3.615 | $3.345 | $3.43 | 1.04M |
| Oct 13, 2026 | $3.62 | $3.62 | $3.395 | $3.40 | 605.46K |
| Oct 12, 2026 | $3.64 | $3.71 | $3.60 | $3.61 | 603.48K |
| Oct 9, 2026 | $3.53 | $3.65 | $3.42 | $3.645 | 625.76K |
| Oct 8, 2026 | $3.58 | $3.61 | $3.35 | $3.53 | 1.04M |
| Oct 7, 2026 | $3.72 | $3.72 | $3.58 | $3.62 | 515.5K |
| Oct 6, 2026 | $3.60 | $3.84 | $3.60 | $3.79 | 682.82K |
| Oct 5, 2026 | $3.60 | $3.60 | $3.455 | $3.59 | 777.42K |
The latest Smart Investors Daily articles mentioning LENZ.
Company
Market Activity
Research & News
LENZ research
Company profile and research snapshot.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 29, 2026 | TD Cowen | Buy | — |
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 19, 2026 | Piper Sandler | Neutral | — |
| Aug 12, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 22, 2026
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results. To participate in the conference
Benzinga · Oct 21, 2026
TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $60 to $50.
Yahoo · Oct 21, 2026
LENZ Therapeutics is under fresh scrutiny after analysts cut price targets, including moves from US$7 to US$5 and from US$20 to US$10. These changes are closely tied to updated research that weighs confidence in the VIZZ asset against questions around a slower presbyopia launch, revenue ramp and how a single product story supports the current valuation. As you read on, you will see how to track this evolving LENZ Therapeutics narrative and what to watch in the next leg of the story. Analyst...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LENZ.
